Suzhou Zelgen BiopharmaceuticalsLtd Balance Sheet Health
Financial Health criteria checks 4/6
Suzhou Zelgen BiopharmaceuticalsLtd has a total shareholder equity of CN¥1.3B and total debt of CN¥893.5M, which brings its debt-to-equity ratio to 68.6%. Its total assets and total liabilities are CN¥3.0B and CN¥1.7B respectively.
Key information
68.6%
Debt to equity ratio
CN¥893.53m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥2.20b |
| Equity | CN¥1.30b |
| Total liabilities | CN¥1.66b |
| Total assets | CN¥2.97b |
Recent financial health updates
No updates
Recent updates
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors
Nov 27
Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 11What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates
May 08Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 06Financial Position Analysis
Short Term Liabilities: 688266's short term assets (CN¥2.6B) exceed its short term liabilities (CN¥1.3B).
Long Term Liabilities: 688266's short term assets (CN¥2.6B) exceed its long term liabilities (CN¥350.7M).
Debt to Equity History and Analysis
Debt Level: 688266 has more cash than its total debt.
Reducing Debt: 688266's debt to equity ratio has increased from 15.1% to 68.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688266 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 688266 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 09:56 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyu He | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |
| Yinhao Tang | Citic Securities Co., Ltd. |